Cargando…
Mycolicibacterium brumae is a Safe and Non-Toxic Immunomodulatory Agent for Cancer Treatment
Intravesical Mycobacterium bovis Bacillus Calmette–Guérin (BCG) immunotherapy remains the gold-standard treatment for non-muscle-invasive bladder cancer patients, even though half of the patients develop adverse events to this therapy. On exploring BCG-alternative therapies, Mycolicibacterium brumae...
Autores principales: | Bach-Griera, Marc, Campo-Pérez, Víctor, Barbosa, Sandra, Traserra, Sara, Guallar-Garrido, Sandra, Moya-Andérico, Laura, Herrero-Abadía, Paula, Luquin, Marina, Rabanal, Rosa Maria, Torrents, Eduard, Julián, Esther |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349652/ https://www.ncbi.nlm.nih.gov/pubmed/32344808 http://dx.doi.org/10.3390/vaccines8020198 |
Ejemplares similares
-
Draft Genome Sequence of Mycobacterium brumae ATCC 51384
por: D'Auria, Giuseppe, et al.
Publicado: (2016) -
Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype
por: Renau-Mínguez, Chantal, et al.
Publicado: (2023) -
The High Plasticity of Nonpathogenic Mycobacterium brumae Induces Rapid Changes in Its Lipid Profile during Pellicle Maturation: The Potential of This Bacterium as a Versatile Cell Factory for Lipid Compounds of Therapeutic Interest
por: Campo-Pérez, Víctor, et al.
Publicado: (2022) -
BCG Substrains Change Their Outermost Surface as a Function of Growth Media
por: Guallar-Garrido, Sandra, et al.
Publicado: (2021) -
Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice
por: Noguera-Ortega, Estela, et al.
Publicado: (2018)